The company’s first appearance at this prestigious cancer research conference profiles use cases of platform for cancer treatment planning and as a cancer research tool.

Genoa Ventures and Northpond Ventures co-lead investment in precision medicine platform that develops virtual tumors in 3D to predict response to therapy using standard-of-care data